Ang2 is another factor that promotes new abnormal blood vessel formation. This 7-month study will help determine if this new combination drug better preserves the vision of patients with DME. Treatments will be provided free of charge.
For more information about the VRMNY retina eye specialists or to see if you qualify for the study, contact our research department at email@example.com or (212) 452-6965. You may also visit the BOULEVARD Clinical Trials website.
Let us help you enjoy your lifeCall: (212) 861-9797
To Speak With An Appointment Coordinator Now